摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-pentylquinazoline-2,4(1H,3H)-dione

中文名称
——
中文别名
——
英文名称
1-pentylquinazoline-2,4(1H,3H)-dione
英文别名
1-Pentylquinazoline-2,4-dione
1-pentylquinazoline-2,4(1H,3H)-dione化学式
CAS
——
化学式
C13H16N2O2
mdl
——
分子量
232.282
InChiKey
FCEKEJGDIPKQAS-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.4
  • 重原子数:
    17
  • 可旋转键数:
    4
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.38
  • 拓扑面积:
    49.4
  • 氢给体数:
    1
  • 氢受体数:
    2

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    N-异丙基氯乙酰氨1-pentylquinazoline-2,4(1H,3H)-dionepotassium carbonate 作用下, 以 N,N-二甲基甲酰胺 为溶剂, 以99%的产率得到2-(2,4-dioxo-1-pentyl-1,2-dihydroquinazolin-3(4H)-yl)-N-isopropylacetamide
    参考文献:
    名称:
    Development of Quinazoline/Pyrimidine-2,4(1H,3H)-diones as Agonists of Cannabinoid Receptor Type 2
    摘要:
    Starting from a prototypical structure 1, we describe our efforts to design and obtain novel quinazoline/ pyrimidine-2,4(1H,3H)-diones with high CB2 agonist potency and selectivity as well as improved physicochemical characteristics, mainly hydrophilicity. The most potent and selective CB2 agonists, 8 and 36, in this series were also endowed with lower logP values than that of GW842166X and lead compound 1. These derivatives appear to be promising lead compounds for the development of future CB2 agonists.
    DOI:
    10.1021/acsmedchemlett.7b00007
  • 作为产物:
    描述:
    邻氨基苯甲酸potassium carbonate 、 potassium iodide 作用下, 以 乙腈 为溶剂, 反应 25.5h, 生成 1-pentylquinazoline-2,4(1H,3H)-dione
    参考文献:
    名称:
    Development of Quinazoline/Pyrimidine-2,4(1H,3H)-diones as Agonists of Cannabinoid Receptor Type 2
    摘要:
    Starting from a prototypical structure 1, we describe our efforts to design and obtain novel quinazoline/ pyrimidine-2,4(1H,3H)-diones with high CB2 agonist potency and selectivity as well as improved physicochemical characteristics, mainly hydrophilicity. The most potent and selective CB2 agonists, 8 and 36, in this series were also endowed with lower logP values than that of GW842166X and lead compound 1. These derivatives appear to be promising lead compounds for the development of future CB2 agonists.
    DOI:
    10.1021/acsmedchemlett.7b00007
点击查看最新优质反应信息

文献信息

  • 喹唑啉二酮类衍生物及其制备方法和用途
    申请人:浙江大学
    公开号:CN106146414A
    公开(公告)日:2016-11-23
    本发明提供一种新的喹唑啉二酮类衍生物及其制备方法和用途,该类化合物包括具有通式V所示结构的化合物及其药学上可接受的盐或水合物。本发明提供的化合物是新型大麻素II型受体CB2的活性配体,可制备治疗、预防和缓解由CB2受体介导的疾病的药物。所述药物为大麻素CB2受体的激动剂、部分激动剂、反向激动剂或拮抗剂。结构通式V为:。
  • Novel Ethanediamone Hepcidine Antagonists
    申请人:Dürrenberger Franz
    公开号:US20120214798A1
    公开(公告)日:2012-08-23
    The present invention relates to novel hepcidin antagonists of formula (I), pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for treatment of disorders in iron metabolism, such as, in particular, iron deficiency diseases and anaemias, in particular anaemias in connection with chronic inflammatory diseases (ACD: anaemia of chronic disease and AI: anaemia of inflammation).
    本发明涉及一种新型的肝铁蛋白拮抗剂,其化学式为(I),包括它们的药物组合物以及将其用作药物的用途,特别是用于治疗铁代谢紊乱,如特别是铁缺乏病和贫血等疾病,特别是与慢性炎症性疾病相关的贫血(ACD:慢性疾病性贫血和AI:炎症性贫血)。
  • Verfahren zur Herstellung von substituierten Chinazolin-2,4-dionen
    申请人:Clariant GmbH
    公开号:EP0712849B1
    公开(公告)日:2001-01-17
  • Development of Quinazoline/Pyrimidine-2,4(1<i>H</i>,3<i>H</i>)-diones as Agonists of Cannabinoid Receptor Type 2
    作者:Hai-Yan Qian、Zhi-Long Wang、You-Lu Pan、Li-Li Chen、Xin Xie、Jian-Zhong Chen
    DOI:10.1021/acsmedchemlett.7b00007
    日期:2017.6.8
    Starting from a prototypical structure 1, we describe our efforts to design and obtain novel quinazoline/ pyrimidine-2,4(1H,3H)-diones with high CB2 agonist potency and selectivity as well as improved physicochemical characteristics, mainly hydrophilicity. The most potent and selective CB2 agonists, 8 and 36, in this series were also endowed with lower logP values than that of GW842166X and lead compound 1. These derivatives appear to be promising lead compounds for the development of future CB2 agonists.
查看更多